Vebreltinib (APL-101)

About Apollomics

Apollomics is a clinical-stage biotech focused on developing oncology combination therapies. The company's pipeline includes assets like vebreltinib (APL-101), targeting cancers with specific genetic alterations, and other candidates in earlier stages. With a vision to become a global leader in oncology innovation, Apollomics emphasizes a science-driven approach to address unmet needs in patients who have exhausted treatment options.

Therapeutic Areas